Since its approval in the late 1980s for the treatment of rheumatoid arthritis (RA), methotrexate has been the yardstick against which all other therapeutic agents against this disease, including the ...

Patients who take methotrexate for a variety of immune-mediated inflammatory diseases and pause taking the drug following receipt of a COVID-19 vaccine dose did not have a higher risk of disease flare ...

Adding methotrexate to adalimumab (Humira) in axial spondyloarthritis was associated with reduced immunogenicity, as shown by a lower rate of developing antidrug antibodies, French researchers ...

Methotrexate reduces cardiovascular risk in patients with inflammatory disease but not in the general population. Methotrexate (MTX) reduces cardiovascular risk in patients with rheumatoid arthritis ...

Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...

At week 52 in a randomized, controlled trial, results suggest that tocilizumab is more effective than methotrexate in ...

Methotrexate comes as an injection given under your skin or into your muscle. It also comes as a tablet you swallow and an intravenous (IV) infusion (an injection into your vein given over time). But ...

The result of an unblinded, multicenter, randomized phase III clinical trial (VESPER) was recently published by Pfister et al. 1 This study aimed to explore the optimal perioperative chemotherapy ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

If you’re looking at treatment options for psoriasis, arthritis, or certain kinds of cancer, you may want to learn more about methotrexate. For more details on methotrexate’s uses and more, see this ...

Soon after she started taking the drug methotrexate in February, Jennifer Crow noticed a significant improvement in her inflammatory arthritis pain. Since then, she’s taken the drug weekly. So her ...

Ian Millhiser is a senior correspondent at Vox, where he focuses on the Supreme Court, the Constitution, and the decline of liberal democracy in the United States. He received a JD from Duke ...